A Study of LAD603 in Adults With Alopecia Areata
← catalyst calendarNCT07311564 · readout in 308 d
Sponsored by Almirall, S.A. (industry) · ALM.MC — their whole pipeline →.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Randomized · Double · Treatment
Enrollment
136estimated
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-12-17 | actual | When the study began enrolling |
| Primary completion | 2027-06-23 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-11-21 | estimated | The whole study's end, after follow-up |
| First posted | 2025-12-31 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-05-20 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Alopecia Areata
Interventions
- Drug: LAD603
- Other: Placebo
Primary outcome
what the primary-completion date above is the date OFPercent Change from Baseline in the Severity of Alopecia Tool (SALT) Score
measured Baseline, Week 28
Permalink · ALM.MC's whole pipeline · Catalyst calendar · Every registered study · What changed